Clinical Trial Update: Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating pembrolizumab in combination with intravesical BCG solution for recurrent non-muscle-invasive bladder cancer; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• BCG (Bacillus Calmette-Guérin) intravesical solution (Bacillus Calmette-Guérin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2022-10-20